These results were evaluated in tumors such as melanoma and NSCLC [42,43,44], showing that patients with low levels of CD8+ PD-1+ T cells in peripheral blood at the start of immunotherapy treatment were those with the most durable responses to treatment. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.